Navigation Links
Lonza Houston Cell and Viral Gene Therapy Manufacturing Facility Wins 2018 ENR Regional Award for Best Project
Date:8/9/2018

CRB is proud to announce that the Lonza Houston Inc. cell and viral gene therapy manufacturing facility has won Engineering News-Record (ENR) Texas & Louisiana’s 2018 Best Projects in the Manufacturing category. A total of 121 entries were submitted for the Best Projects competition. The judges selected 42 projects across 18 categories as the region’s best. Projects were scored on the ability of the project team to overcome challenges, contribution to the industry and community, project innovation, safety and construction/design quality.

CRB’s Dallas office leader, Ashley Frosell, PE, stated, “CRB is extremely proud to be a part of a project that will have such a profound and direct impact on the advancement of revolutionary new cell and gene therapies. We are honored that Lonza trusted our Texas-based team to help translate this initiative into reality.”

Lonza Houston is 300,000-square-foot state-of-the-art facility located on an 11-acre site in Pearland’s Lower Kirby District, just outside Houston, Texas. This project stemmed from the intent to move existing clinical operations out of a location that could no longer support the anticipated operational growth.

CRB provided design-build services to create a 170,000-square-foot greenfield space to house the viral-based cell and gene therapeutics manufacturing operation with an additional 130,000 square feet readily available expansion space to house the anticipated growth of this operation. Clean rooms were designed to manufacture cell therapy and viral gene therapy products to meet the growing demand for products in the U.S. and European markets. Lonza Houston is now the world’s largest dedicated cell and gene therapy manufacturing with process development capabilities bringing products from concept to patient.

"Lonza Houston will serve as a center of excellence for cell and gene therapy process development from concept through pre-clinical, clinical and commercialization, all the way to the patient," Thomas Fellner, Head of cell & gene therapy at Lonza Pharma & Biotech, said. "This facility has the potential to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases, under one roof. It will set a new standard in biopharmaceutical manufacturing and stand as one of four centers of excellence in cell and gene therapy in the only global network spanning three continents."

This project also encountered a formidable challenge halfway through construction that was unlike anything experienced in the area: Hurricane Harvey. Dropping over 40 inches of rain in a four-day period and ultimately causing $125 billion in damage and claiming 88 lives in the region, it was through intense collaboration and teamwork by individuals who had lived and worked through other storms like Hurricane Katrina that the team was able to effectively prepare for and overcome such a significant hurdle.

CRB and Lonza will be recognized at the ENR Texas & Louisiana Best Projects awards ceremony in Houston on October 18, 2018.

About CRB:
CRB is a full-service network of engineers, architects, constructors and consultants assisting advanced technology organizations in the planning, design, construction and operational support of facilities across the globe. With world-class technical expertise and an empowered team of 1,000-plus, we relentlessly pursue and deliver the right solutions to our clients’ technical challenges, no matter how big or small. Since 1984, CRB has earned a reputation for providing value-based solutions, delivering superior quality work and developing long-term partnerships built on trust and productive collaboration. For more information, visit crbusa.com.

About Lonza:
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. Founded in 1897 in the Swiss Alps, Lonza today is a well- respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. Further information can be found at lonza.com.

Read the full story at https://www.prweb.com/releases/lonza_houston_cell_and_viral_gene_therapy_manufacturing_facility_wins_2018_enr_regional_award_for_best_project/prweb15680193.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. Amarantus and Lonza Walkersville, Inc. Provide Update on cGMP Manufacturing Readiness for the Engineered Skin Substitute (ESS) Program
2. University of Houston researcher publishes textbook on tissue engineering
3. How much does African dust add to Houstons pollution?
4. Sam Houston State studies DNA preservation in mass disasters
5. University of Houston engineering professor awarded grant to study melanoma treatment
6. Team determines structure of a molecular machine that targets viral DNA for destruction
7. Tiniest catch: University of Arizona scientists fishing expedition reveals viral diversity in the sea
8. Starting signal for antiviral defense
9. Viral infections: Identifying the tell-tale patterns
10. Nanocrystalline cellulose modified into an efficient viral inhibitor
11. Degradation of viral DNA in the cell nucleus is opening up new treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2018)... ... November 27, 2018 , ... ... have worked together to integrate the LabArchives Classroom Edition with Current Protocols Essential ... will be available beginning January of 2019. , The integration of ...
(Date:11/20/2018)... (PRWEB) , ... November 19, 2018 , ... ... by Applications (academic research tools, drug development, agriculture, human clinical therapeutics, and animal ... breeding products), by Technology (drug compound and target screening, and agriculture and industrial ...
(Date:11/20/2018)... ... November 20, 2018 , ... Like many large breed dogs, Jack, a ... was a year old, his mom, Rebecca, noticed he was slow to get up ... veterinarian and her suspicions were confirmed: Jack had bilateral hip dysplasia, a congenital condition ...
Breaking Biology News(10 mins):
(Date:11/6/2018)... ... November 06, 2018 , ... Crucial ... trial data collection and management. TrialKit ™, an eClinical platform, has incorporated ... can quickly and easily sign in to the app via facial recognition or ...
(Date:11/5/2018)... ... November 05, 2018 , ... GlycoMark, Inc., ... healthcare professionals through its website, http://www.glycomark.com , as part of National Diabetes ... video option via the website in November from 9 a.m. – 5 p.m. ...
(Date:11/3/2018)... (PRWEB) , ... November 01, 2018 , ... Triangle Insights ... Inc. Magazine as one of the fastest-growing private companies in the United States, appearing ... 5000 list ranks private companies based on percentage revenue growth over the previous three ...
(Date:10/31/2018)... ... ... young Labrador retriever. Like most labs, Pippa is energetic, crazy, and fun-loving. When ... in her right knee. According to her mom, Kinsley, Pippa was limping constantly and ... heart to see Pippa lie around in pain because it hurt too much to play. ...
Breaking Biology Technology: